The lack of Ahr activation in our study is therefore consistent with the assumption that short-term cognitive deficits induced by scopolamine do not involve molecular mechanisms typical of chronic oxidative stress and neurodegeneration. The gene discussed is AHR; the disease is Cognitive impairment.